BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB) was the target of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 3,180,000 shares, a decline of 17.0% from the February 13th total of 3,830,000 shares. Approximately 7.4% of the shares of the company are sold short. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is presently 2.9 days.

BioAtla Trading Up 0.3 %

Shares of BCAB opened at $0.36 on Thursday. The firm has a market cap of $17.21 million, a PE ratio of -0.21 and a beta of 1.19. The firm has a fifty day simple moving average of $0.42 and a two-hundred day simple moving average of $1.20. BioAtla has a 1-year low of $0.24 and a 1-year high of $4.02.

Institutional Investors Weigh In On BioAtla

A number of hedge funds have recently added to or reduced their stakes in BCAB. Anson Funds Management LP purchased a new stake in shares of BioAtla in the 4th quarter worth $2,720,000. Acorn Capital Advisors LLC purchased a new stake in shares of BioAtla in the 4th quarter worth $2,384,000. Highbridge Capital Management LLC purchased a new stake in shares of BioAtla in the 4th quarter worth $1,484,000. Boxer Capital Management LLC purchased a new stake in shares of BioAtla in the 4th quarter worth $406,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of BioAtla in the 4th quarter worth $383,000. 77.23% of the stock is currently owned by hedge funds and other institutional investors.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.